K Fizazi1, T W Flaig2, M Stöckle3, H I Scher4, J S de Bono5, D E Rathkopf4, C J Ryan6, T Kheoh7, J Li8, M B Todd9, T W Griffin10, A Molina11, C H Ohlmann3. 1. Institut Gustave Roussy, University of Paris Sud, Villejuif, France karim.fizazi@igr.fr. 2. University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, USA. 3. Saarland University, Homburg/Saar, Germany. 4. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA. 5. The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. 6. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco. 7. Janssen Research & Development, San Diego. 8. Janssen Research & Development, Raritan. 9. Janssen Global Services, Raritan. 10. Janssen Research & Development, Los Angeles. 11. Janssen Research & Development, Menlo Park, USA.
Abstract
BACKGROUND: The usefulness of Gleason score (<8 or ≥8) at initial diagnosis as a predictive marker of response to abiraterone acetate (AA) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) was explored retrospectively. PATIENTS AND METHODS: Initial diagnosis Gleason score was obtained in 1048 of 1195 (COU-AA-301, post-docetaxel) and 996 of 1088 (COU-AA-302, chemotherapy-naïve) patients treated with AA 1 g plus prednisone 5 mg twice daily by mouth or placebo plus prednisone. Efficacy end points included radiographic progression-free survival (rPFS) and overall survival (OS). Distributions and medians were estimated by Kaplan-Meier method and hazard ratio (HR) and 95% confidence interval (CI) by Cox model. RESULTS: Baseline characteristics were similar across studies and treatment groups. Regardless of Gleason score, AA treatment significantly improved rPFS in post-docetaxel [Gleason score <8: median, 6.4 versus 5.5 months (HR = 0.70; 95% CI 0.56-0.86), P = 0.0009 and Gleason score ≥8: median, 5.6 versus 2.9 months (HR = 0.58; 95% CI 0.48-0.72), P < 0.0001] and chemotherapy-naïve patients [Gleason score <8: median, 16.5 versus 8.2 months (HR = 0.50; 95% CI 0.40-0.62), P < 0.0001 and Gleason score ≥8: median, 13.8 versus 8.2 months (HR = 0.61; 95% CI 0.49-0.76), P < 0.0001]. Clinical benefit of AA treatment was also observed for OS, prostate-specific antigen (PSA) response, objective response and time to PSA progression across studies and Gleason score subgroups. CONCLUSION: OS and rPFS trends demonstrate AA treatment benefit in patients with pre- or post-chemotherapy mCRPC regardless of Gleason score at initial diagnosis. The initial diagnostic Gleason score in patients with mCRPC should not be considered in the decision to treat with AA, as tumour metastases may no longer reflect the histology at the time of diagnosis. CLINICAL TRIALS NUMBER: COU-AA-301 (NCT00638690); COU-AA-302 (NCT00887198).
BACKGROUND: The usefulness of Gleason score (<8 or ≥8) at initial diagnosis as a predictive marker of response to abiraterone acetate (AA) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) was explored retrospectively. PATIENTS AND METHODS: Initial diagnosis Gleason score was obtained in 1048 of 1195 (COU-AA-301, post-docetaxel) and 996 of 1088 (COU-AA-302, chemotherapy-naïve) patients treated with AA 1 g plus prednisone 5 mg twice daily by mouth or placebo plus prednisone. Efficacy end points included radiographic progression-free survival (rPFS) and overall survival (OS). Distributions and medians were estimated by Kaplan-Meier method and hazard ratio (HR) and 95% confidence interval (CI) by Cox model. RESULTS: Baseline characteristics were similar across studies and treatment groups. Regardless of Gleason score, AA treatment significantly improved rPFS in post-docetaxel [Gleason score <8: median, 6.4 versus 5.5 months (HR = 0.70; 95% CI 0.56-0.86), P = 0.0009 and Gleason score ≥8: median, 5.6 versus 2.9 months (HR = 0.58; 95% CI 0.48-0.72), P < 0.0001] and chemotherapy-naïve patients [Gleason score <8: median, 16.5 versus 8.2 months (HR = 0.50; 95% CI 0.40-0.62), P < 0.0001 and Gleason score ≥8: median, 13.8 versus 8.2 months (HR = 0.61; 95% CI 0.49-0.76), P < 0.0001]. Clinical benefit of AA treatment was also observed for OS, prostate-specific antigen (PSA) response, objective response and time to PSA progression across studies and Gleason score subgroups. CONCLUSION: OS and rPFS trends demonstrate AA treatment benefit in patients with pre- or post-chemotherapy mCRPC regardless of Gleason score at initial diagnosis. The initial diagnostic Gleason score in patients with mCRPC should not be considered in the decision to treat with AA, as tumour metastases may no longer reflect the histology at the time of diagnosis. CLINICAL TRIALS NUMBER: COU-AA-301 (NCT00638690); COU-AA-302 (NCT00887198).
Authors: Andrew J Armstrong; Ian F Tannock; Ronald de Wit; Daniel J George; Mario Eisenberger; Susan Halabi Journal: Eur J Cancer Date: 2009-12-11 Impact factor: 9.162
Authors: Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small Journal: J Clin Oncol Date: 2014-01-21 Impact factor: 44.544
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: N Engl J Med Date: 2014-09-03 Impact factor: 91.245
Authors: Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono Journal: Lancet Oncol Date: 2012-09-18 Impact factor: 41.316
Authors: Peter F A Mulders; Arturo Molina; Michael Marberger; Fred Saad; Celestia S Higano; Kim N Chi; Jinhui Li; Thian Kheoh; Christopher M Haqq; Karim Fizazi Journal: Eur Urol Date: 2013-09-20 Impact factor: 20.096
Authors: Charles J Ryan; Arturo Molina; Jinhui Li; Thian Kheoh; Eric J Small; Christopher M Haqq; Russell P Grant; Johann S de Bono; Howard I Scher Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: O B Goodman; T W Flaig; A Molina; P F A Mulders; K Fizazi; H Suttmann; J Li; T Kheoh; J S de Bono; H I Scher Journal: Prostate Cancer Prostatic Dis Date: 2013-10-01 Impact factor: 5.554
Authors: R R McKay; L Werner; M Fiorillo; M Nakabayashi; P W Kantoff; M-E Taplin Journal: Prostate Cancer Prostatic Dis Date: 2016-08-09 Impact factor: 5.554
Authors: Moritz Binder; Ben Y Zhang; David W Hillman; Rhea Kohli; Tanvi Kohli; Adam Lee; Manish Kohli Journal: Int J Mol Sci Date: 2016-07-09 Impact factor: 5.923
Authors: K Kobayashi; N Okuno; G Arai; H Nakatsu; A Maniwa; N Kamiya; T Satoh; H Kikukawa; Y Nasu; H Uemura; T Nakashima; K Mikami; M Iinuma; K Tanabe; J Furukawa; H Kobayashi Journal: Jpn J Clin Oncol Date: 2021-04-01 Impact factor: 3.019